Research: 2016–present

🐀 = animal study      🧬 = genetics focus      📚 = systematic review / meta-analysis

Jump to: 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2011–2015 | 2000–2010 | 1942–1999


2022 papers are categorized by specialty and topic, while papers in prior years are in alphabetical order by first author.


Björnebo L, Nordström T, Discacciati A, et al. Association of 5α-reductase inhibitors with prostate cancer mortality. JAMA Oncol. 2022 Jul 1. doi:10.1001/jamaoncol.2022.1501. Erratum in: JAMA Oncol. 2022 Jun 16. PubMed

Garg H, Wheeler KM, Dursun F, et al. Impact of finasteride on survival in bladder cancer: a retrospective multi-institutional database analysis. Clin Genitourin Cancer. 2022 Oct. doi:10.1016/j.clgc.2022.10.014PubMed

Rabbani S, Santoni G, Lagergren J, Xie SH. Use of anti-androgenic 5α-reductase inhibitors and risk of oesophageal and gastric cancer by histological type and anatomical sub-site. Br J Cancer. 2022 Jun 17. doi:10.1038/s41416-022-01872-wPubMed

Dekalo S, McArthur E, Campbell J, Ordon M, Power N, Welk B. 5α-reductase inhibitors and the risk of bladder cancer in a large, population-based cohort. Urol Oncol. 2022 Oct 29. doi:10.1016/j.urolonc.2022.09.004PubMed


[⚠️ Funded by GSK] Choi GS, Sim WY, Kang H, et al. Long-term effectiveness and safety of dutasteride versus finasteride in patients with male androgenic alopecia in South Korea: a multicentre chart review study. Ann Dermatol. 2022 Oct. doi:10.5021/ad.22.027PubMed

🐀 da Cruz GK, Martins MIM, Antunes FTT, et al. Evaluation of the efficacy and toxicity of oral and topical pumpkin oil on the hair growth of mice. Acta Histochem. 2022 Apr 18. doi:10.1016/j.acthis.2022.151894PubMed [Includes finasteride treatment group]

Gupta AK, Talukder M. Topical finasteride for male and female pattern hair loss: Is it a safe and effective alternative? J Cosmet Dermatol. 2022 May. doi:10.1111/jocd.14895PubMed

Gupta AK, Talukder M, Williams G. Comparison of oral minoxidil, finasteride, and dutasteride for treating androgenetic alopecia. J Dermatolog Treat. 2022 Aug 3. doi:10.1080/09546634.2022.2109567PubMed

Huang KP, Senna MM. Hair are the rankings—5-α reductase inhibitors and minoxidil in male androgenetic alopecia. JAMA Dermatol. 2022 Feb 2. doi:10.1001/jamadermatol.2021.5625PubMed

Hui EX, Huang X, Oon HH. Review of dermatologic medications and impact on male fertility, sexual dysfunction and teratogenicity. Andrology. 2022 Oct. doi:10.1111/andr.13236 • PubMed

Melo DF, Saceda-Corralo D, Tosti A. Frontal edema due to mesotherapy for androgenetic alopecia: a case series. Dermatol Ther. 2022 Feb. doi:10.1111/dth.15247 • PubMed

Reguero Del Cura L, De Quintana Sancho A, Rubio Lombraña M, López Sundh AE, González López MA. Two cases of paradoxical nonscarring alopecia after mesotherapy with dutasteride. Skin Appendage Disord. 2022 Jan. doi:10.1159/000518043PubMed

Sand J, Walen S. Noninvasive hair rejuvenation. Facial Plast Surg Clin North Am. 2022 Aug. doi:10.1016/j.fsc.2022.03.015PubMed

Trüeb RM, Luu NC, Gavazzoni Dias MFR, Dutra Rezende H. How to deal with the issues of fertility, malignancies, and the postfinasteride syndrome while prescribing finasteride for male pattern hair loss. Skin Appendage Disord. 2022 May. doi:10.1159/000520493 • PubMed

Yanagisawa M, Sato A. Long-term (over 10 years) evaluation of efficacy and safety of finasteride in Japanese men with androgenetic alopecia: summary of three investigations. Hair Transplant Forum International. 2022 Jul;32(4):130-132. doi:10.33589/32.4.130.


Rzeszotek S, Kolasa A, Pilutin A, Misiakiewicz-Has K, Sielatycka K, Wiszniewska B. The interplay between finasteride-induced androgen imbalance, endoplasmic reticulum stress, oxidative stress, and liver disorders in paternal and filial generation. Biomedicines. 2022. doi:10.3390/biomedicines10112725

Neuroendocrinology & neuropharmacology

🐀 Dhillon HK, Singh T, Goel RK. Ferulic acid inhibits catamenial epilepsy through modulation of female hormones. Metab Brain Dis. 2022 Aug 6. doi:10.1007/s11011-022-01054-w • PubMed [Finasteride increased seizure susceptibility and depression-like characteristics]

🐀 Diviccaro S, Giatti S, Cioffi L, et al. Gut inflammation induced by finasteride withdrawal: therapeutic effect of allopregnanolone in adult male rats. Biomolecules. 2022. doi:10.3390/biom12111567 • Link via journal

Ocular effects

Calvao J, Feijão J, Soares RO. Finasteride and floppy iris syndrome: What role can the dermatologist play? [Letter]. Int J Trichology. 2022 May-Jun. doi:10.4103/ijt.ijt_118_20PubMedPMC full text

📚 Christou CD, Esagian SM, Ziakas N, Prousali E, Tzamalis A. Factors predisposing to intraoperative floppy iris syndrome (IFIS): an updated systematic review and meta-analysis. J Cataract Refract Surg. 2022 Jul 20. doi:10.1097/j.jcrs.0000000000001017PubMed

Pharmacovigilance & drug safety

Asanad K, Sholklapper T, Samplaski MK, Cacciamani GE. Global online interest in finasteride sexual side effects. Int J Impot Res. 2022. doi:10.1038/s41443-022-00612-1PubMed

Gordijn R, Wessels W, Kriek E, et al. Patient reporting of sexual adverse events on an online platform for medication experiences. Br J Clin Pharmacol. 2022 Jul 2. doi:10.1111/bcp.15454PubMed

Hui EX, Huang X, Oon HH. Review of dermatologic medications and impact on male fertility, sexual dysfunction and teratogenicity. Andrology. 2022 Oct. doi:10.1111/andr.13236 • PubMed

Kaplan-Marans E, Sandozi A, Martinez M, Lee J, Schulman A, Khurgin J. Medications most commonly associated with erectile dysfunction: evaluation of the Food and Drug Administration national pharmacovigilance database. Sex Med. 2022. doi:10.1016/j.esxm.2022.100543 (full text available) • PubMed

Nguyen DD, Herzog P, Cone EB, et al. Disproportional signal of sexual dysfunction reports associated with finasteride use in young men with androgenetic alopecia: a pharmacovigilance analysis of VigiBase. J Am Acad Dermatol. 2022 Mar 26. doi:10.1016/j.jaad.2022.03.037PubMed

Schifano N, Capogrosso P, Boeri L, et al. Are finasteride-related penile curvature/Peyronie’s disease adverse event reports worthy of further clinical investigation? Disproportionality analysis based on both the Food and Drug Administration (FDA) and the European Medicines Agency (EMA) pharmacovigilance databases. Int J Impot Res. 2022 May 5. doi:10.1038/s41443-022-00568-2 • PubMed

Valeiro C, Matos C, Scholl J, van Hunsel F. Drug-induced sexual dysfunction: an analysis of reports to a national pharmacovigilance database. Drug Saf. 2022 Apr 7. doi:10.1007/s40264-022-01174-3 • PubMed

Yeon B, Suh AY, Choi E, et al. Depression risk associated with the use of 5α-reductase inhibitors versus α-blockers: a retrospective cohort study in South Korea. PLoS One. 2022 Mar 16. doi:10.1371/journal.pone.0265169PubMedPMC full text

📚 Zhang JJ, Shi X, Wu T, et al. Sexual, physical, and overall adverse effects in patients treated with 5α-reductase inhibitors: a systematic review and meta-analysis. Asian J Androl. 2022 Jul-Aug. doi:10.4103/aja202171PubMed

See also: In Dermatology: Hui et al., 2022. In Post-finasteride syndrome: Irwig, 2022.

Post-finasteride syndrome

Alhetheli GI, Alrashidi FH, Alhammad SH. Post-finasteride syndrome: current views and where do we stand?. Ann Med Health Sci Res. 2022 Jan 24. doi:10.54608/annalsmedical.2022.23 • via Internet Archive

Irwig MS. How routine pharmacovigilance failed to identify finasteride’s persistent sexual side effects. Andrology. 2022. doi:10.1111/andr.13122PubMed

Romero Pérez P. Post-finasteride syndrome. Literature review. Arch Esp Urol. 2022 Jun. doi:10.56434/j.arch.esp.urol.20227505.56PubMed

Li X, Guo Y, Lu Y, et al. Case report: a study of the clinical characteristics and genetic variants of post-finasteride syndrome patients. Transl Androl Urol. 2022 Oct. doi:10.21037/tau-22-92 • PubMedPMC full text

See also: In Dermatology: Trüeb et al., 2022. In Pharmacovigilance & drug safety: Schifano et al., 2022; and Zhang et al., 2022.

Urology & sexual medicine

🐀 Flores RB, Angrimani DSR, Brito MM, et al. Frozen-thawed sperm analysis of benign prostatic hyperplasia dogs treated with finasteride. Front Vet Sci. 2022 Jun 30. doi:10.3389/fvets.2022.901943 • PubMedPMC full text

📚 Li Y, Ma J, Qin XH, Hu CY. The efficacy and safety of dutasteride and finasteride in patients with benign prostatic hyperplasia: a systematic review and meta-analysis. Transl Androl Urol. 2022 Mar. doi:10.21037/tau-22-58PubMedPMC full text

[⚠️ Funded by NeoTract/Teleflex, seller of UroLift System] Roehrborn CG, Rukstalis DB. Prostatic urethral lift versus medical therapy: examining the impact on sexual function in men with benign prostatic hyperplasia. Eur Urol Focus. 2022 Jan. doi:10.1016/j.euf.2020.12.013PubMed

🐀 Yilmaz-Oral D, Onder A, Kaya-Sezginer E, Oztekin CV, Zor M, Gur S. Restorative effects of red onion (Allium cepa L.) juice on erectile function after-treatment with 5α-reductase inhibitor in rats. Int J Impot Res. 2022 Apr. doi:10.1038/s41443-021-00421-y • PubMed

See also: In Dermatology: Hui et al., 2022.

2022 abstracts & preprints

Brezis M. Neuropsychiatric reactions to finasteride: nocebo or true effect? Authorea. 2022 Aug 10. doi:10.22541/au.166012115.57216742/v1

Campbell K, Velazquez O, Sullivan J, Lipshultz L. Finasteride-associated suicide and depression in men treated for hypogonadism and impotence. J Sex Med. 2022;19(4):S4-S5. doi:10.1016/j.jsxm.2022.01.019Abstract with chart (PDF) • See also related video in Grey literature: Presentations & webinars

Carlisle M, Uloko M, Yee A, Goldstein S, Goldstein I. Vascular, neurologic and hormonal abnormalities in men with persistent sexual dysfunction after discontinuation of finasteride. J Urol. 2022 May 1;207(5S):e620–621. doi:10.1097/JU.0000000000002592.07Poster (PDF)

🐀 Giatti S, Diviccaro S, Di Domizio A, et al. Finasteride inhibits epinephrine synthesis in humans: implication for sexual dysfunction. Endocrine Abstracts. 2022 May;81:P448. doi:10.1530/endoabs.81.P448

🧬 Ihentuge C, Csoka A. Finasteride induces epigenetic modulation of LSP1: a gene implicated in neutrophil actin dysfunction disease. FASEB J. 2022 May;36 Suppl 1. doi:10.1096/fasebj.2022.36.S1.R4708

Kaplan-Marans E, Martinez M, Sandozi A, Lee J, Khurgin J, Schulman A. PD49-02 Medications most commonly associated with erectile dysfunction: evaluation of the Food and Drug Administration national pharmacovigilance database. J Urol. 2022 May;207 Suppl 5:e830. doi:10.1097/JU.0000000000002620.02 [See paper in Sex Med above]

Nguyen BJ, Meer E, Gupta AS, et al. The effect of finasteride on dry eye disease. Paper presented at: ARVO 2022: Annual Meeting of the Association for Research in Vision and Ophthalmology; May 1, 2022; Denver, CO. Abstract (PDF)

Nguyen D, Herzog P, Cone EB, et al. Pharmacovigilance analysis of reports of sexual dysfunction associated with finasteride use: implications for the post-finasteride syndrome. J Sex Med. 2022;19(5, Supplement 2):S130-S131. doi:10.1016/j.jsxm.2022.03.553 • Direct link on journal website

Nguyen DD, Herzog P, Cone EB, et al. Pharmacovigilance analysis of reports of sexual dysfunction associated with finasteride use: implications for the post-finasteride syndrome (342494). Poster presented at: 41st Congress of the Société Internationale d’Urologie / SIU Academy; November 12, 2021; Dubai, United Arab Emirates. Poster


↑ back to top

🐀 Ahire A, Nair, KP, Shankaranarayana Rao BS, Srikumar BN. The potential involvement of cholinergic system in finasteride induced cognitive dysfunction. Psychoneuroendocrinology. 2021 Feb. doi:10.1016/j.psyneuen.2020.105066PubMed

Ayodele O, Cabral HJ, McManus D, Jick S. The risk of venous thromboembolism (VTE) in men with benign prostatic hyperplasia treated with 5-alpha reductase inhibitors (5ARIs). Clin Epidemiol. 2021 Aug 3. doi:10.2147/CLEP.S317019PubMedPMC full text

Bearelly P, Avellino GJ. The role of benign prostatic hyperplasia treatments in ejaculatory dysfunction. Fertil Steril. 2021 Sep. doi:10.1016/j.fertnstert.2021.07.1199PubMed

Birch MR, Dissing S, Skakkebæk NE, Rehfeld A. Finasteride interferes with prostaglandin-induced CatSper-signalling in human sperm. Reproduction. 2021 Mar 1. doi:10.1530/REP-20-0287PubMed

Borgo F, Macandog AD, Diviccaro S, et al. Alterations of gut microbiota composition in post-finasteride patients: a pilot study. J Endocrinol Invest. 2021 Jun. doi:10.1007/s40618-020-01424-0PubMed • PMC full text

🐀 Da Silva MHA, Estrada JHD, Gregório BM, et al. Does treatment with dutasteride or finasteride has [sic] impact on renal morphology? Experimental study. Acta Cir Bras. 2021 Sep 15. doi:10.1590/ACB360703PubMedPMC full text

Favilla V, Cannarella R, Trovato F, et al. Effects of dutasteride on sex hormones and cerebrospinal steroids in patients treated for benign prostatic hyperplasia. Endocrine. 2021 Sep. doi:10.1007/s12020-021-02675-4PubMed

Gallo E, Maggini V, Lombardi N, et al. Serenoa repens induced erectile dysfunction: underdiagnosis and phytovigilance. Br J Clin Pharmacol. 2021 Nov 7. doi:10.1111/bcp.15129 • PubMed

Gao JL, Streed CG Jr, Thompson J, Dommasch ED, Peebles JK. Androgenetic alopecia in transgender and gender diverse populations: a review of therapeutics. J Am Acad Dermatol. 2021 Oct. doi:10.1016/j.jaad.2021.08.067PubMed

Giatti S, Di Domizio A, Diviccaro S, et al. Three-dimensional proteome-wide scale screening for the 5-alpha reductase inhibitor finasteride: identification of a novel off-target. J Med Chem. 2021 Apr 22. doi:10.1021/acs.jmedchem.0c02039PubMedPMC full text

Gupta AK, Venkataraman M, Talukder M, Bamimore MA. Finasteride for hair loss: a review. J Dermatolog Treat. 2021 Jul 22. doi:10.1080/09546634.2021.1959506 • PubMed

Healy D, Bahrick A, Bak M, et al. Diagnostic criteria for enduring sexual dysfunction after treatment with antidepressants, finasteride and isotretinoin. Int J Risk Saf Med. 2021 Oct 26. doi:10.3233/JRS-210023 • PubMed • PMC full text

🧬 Howell S, Song W, Pastuszak A, Khera M. Differential gene expression in post-finasteride syndrome patients. J Sex Med. 2021 Sep. doi:10.1016/j.jsxm.2021.05.009PubMed

Johnstone J, Lusty A, Tohidi M, et al. The association of new-onset diabetes mellitus and medical therapy for benign prostatic hyperplasia: a population-based study. Can Urol Assoc J. 2021 Aug. doi:10.5489/cuaj.7489PubMedPMC full text

Kang MJ, Choi JY, Sim WY, Lew BL. 5α-reductase inhibitors in men aged 50 years or older with androgenetic alopecia: a retrospective study. J Am Acad Dermatol. 2021 Jan. doi:10.1016/j.jaad.2020.04.051PubMed

🐀 🧬 Kolasa A, Rogińska D, Rzeszotek S, Machaliński B, Wiszniewska B. Paternal finasteride treatment can influence the testicular transcriptome profile of male offspring—preliminary study. Curr Issues Mol Biol. 2021 Jul 31. doi:10.3390/cimb43020062PubMed

🐀 🧬 Kur P, Kolasa-Wołosiuk A, Grabowska M, et al. The postnatal offspring of finasteride-treated male rats shows hyperglycaemia, elevated hepatic glycogen storage and altered GLUT2, IR, and AR expression in the liver. Int J Mol Sci. 2021 Jan 27. doi:10.3390/ijms22031242PubMedPMC full text

La Torre A, Palleria C, Tamanini I, et al. Sexual dysfunctions related to drugs used in the management of lower urinary tract symptoms due to benign prostatic hyperplasia: a narrative review on α-blockers and 5-alpha reductase inhibitors. Uro. 2021. doi:10.3390/uro1030012

La Vignera S, Aversa A, Cannarella R, et al. Pharmacological treatment of lower urinary tract symptoms in benign prostatic hyperplasia: consequences on sexual function and possible endocrine effects. Expert Opin Pharmacother. 2021 Feb. doi:10.1080/14656566.2020.1817382PubMed

Loughlin KR. The clinical applications of five-alpha reductase inhibitors. Can J Urol. 2021 Apr. PubMedFull text at journal site

Lulic Z, Son H, Yoo SB, et al. Free combination of dutasteride plus tamsulosin for the treatment of benign prostatic hyperplasia in South Korea: analysis of drug utilization and adverse events using the National Health Insurance Review and Assessment Service database. BMC Urol. 2021 Dec 21. doi:10.1186/s12894-021-00941-1PubMedPMC full text

🐀 Lima CB, Angrimani DSR, Flores RB, Vannucchi CI. Endocrine, prostatic vascular, and proapoptotic changes in dogs with benign prostatic hyperplasia treated medically or surgically. Domest Anim Endocrinol. 2021 Apr. doi:10.1016/j.domaniend.2020.106601 • PubMed

Low P, Li KD, Hakam N, et al. 5-alpha reductase inhibitor related litigation: a legal database review. Andrology. 2021 Dec 21. doi:10.1111/andr.13145PubMed

Lusty A, Siemens DR, Tohidi M, Whitehead M, Tranmer J, Nickel JC. Cardiac failure associated with medical therapy of benign prostatic hyperplasia: a population based study. J Urol. 2021 Feb 22. doi:10.1097/JU.0000000000001561PubMed

Nestor MS, Ablon G, Gade A, Han H, Fischer DL. Treatment options for androgenetic alopecia: efficacy, side effects, compliance, financial considerations, and ethics. J Cosmet Dermatol. 2021 Nov 6. doi:10.1111/jocd.14537PubMed

Oztekin CV, Yilmaz-Oral D, Kaya-Sezginer E, et al. Beneficial effects of human umbilical cord blood mononuclear cells on persistent erectile dysfunction after treatment of 5-alpha reductase inhibitor in rats. J Sex Med. 2021 May. doi:10.1016/j.jsxm.2021.02.005 • PubMed

📚 Pompili M, Magistri C, Maddalena S, Mellini C, Persechino S, Baldessarini RJ. Risk of depression associated with finasteride treatment. J Clin Psychopharmacol. 2021 May-Jun. doi:10.1097/JCP.0000000000001379PubMed

[Follow-up research letter] Baldessarini RJ, Pompili M. Further studies of effects of finasteride on mood and suicidal risk. J Clin Psychopharmacol. 2021 Nov-Dec 01. doi:10.1097/JCP.0000000000001485PubMed

Saengmearnuparp T, Lojanapiwat B, Chattipakorn N, Chattipakorn S. The connection of 5-alpha reductase inhibitors to the development of depression. Biomed Pharmacother. 2021 Aug 31. doi:10.1016/j.biopha.2021.112100PubMedFull text via ScienceDirect

Sattur SS, Sattur IS. Pharmacological management of pattern hair loss. Indian J Plast Surg. 2021 Dec. doi:10.1055/s-0041-1739254PubMedPMC full text

Trüeb RM. Understanding pattern hair loss—hair biology impacted by genes, androgens, prostaglandins and epigenetic factors. Indian J Plast Surg. 2021 Dec. doi:10.1055/s-0041-1739252PubMedPMC full text

Velez D, Ohlander S. Medical therapies causing iatrogenic male infertility. Fertil Steril. 2021 Sep. doi:10.1016/j.fertnstert.2021.07.1202PubMed

🧬 Villapalos-García G, Zubiaur P, et al. Effects of cytochrome P450 and transporter polymorphisms on the bioavailability and safety of dutasteride and tamsulosin. Front Pharmacol. 2021 Oct 7. doi:10.3389/fphar.2021.718281PubMedPMC full text

Yamada T. Photosensitivity reaction induced by finasteride. J Gen Fam Med. 2021 Nov 5. doi:10.1002/jgf2.510PubMedPMC full text

2021 abstracts

Asanad K, Cacciamani GE, Samplaski MK. Consulting “Dr. Google” for finasteride sexual side effects: a contemporary worldwide trends analysis. Fertil Steril. 2021 Sep 1;Suppl 3. doi:10.1016/j.fertnstert.2021.07.912

De Nunzio C, Nacchia A, Lombardo R, et al. Sexual adverse events-related to dutasteride and finasteride: Analysis of real-life data from EudraVigilance database. Presented at 36th Annual EAU Congress (virtual). European Urology. 2021 Jun 1;Suppl 1. doi:10.1016/S0302-2838(21)00427-9

Nguyen DD, Herzog P, Cone EB, et al. Disproportional signal of sexual dysfunction reports associated with finasteride use in young men with androgenetic alopecia: pharmacovigilance analysis of VigiBase. Poster presented at: 22nd Annual Fall Meeting of SMSNA; October 21–24, 2021; Scottsdale, AZ. Poster

Schifano N, Capogrosso P, Boeri L, et al. SC36 – Is finasteride intake associated with penile curvature/Peyronie’s Disease? Assessment of both the Food and Drug Administration (FDA) and the European Medicines Agency (EMA) pharmacovigilance databases. European Urology Open Science. 2021 Oct;32(Suppl 1);S18. doi:10.1016/S2666-1683(21)00727-8 • PDF at ScienceDirect. [See also Schifano et al, 2022 above]


↑ back to top

🧬 Albasher G, Bin-Jumah M, Alfarraj S, et al. Prolonged use of finasteride-induced gonadal sex steroids alterations, DNA damage and menstrual bleeding in women. Biosci Rep. 2020. doi:10.1042/BSR20191434 • PubMed

🐀 Angrimani DSR, Bicudo LC, Llamas Luceño N, et al. Does finasteride treatment for benign prostatic hyperplasia influence sperm DNA integrity in dogs?. Basic Clin Androl. 2020. doi:10.1186/s12610-020-00108-2 • PubMed

🐀 Angrimani DSR, Brito MM, Rui BR, Nichi M, Vannucchi CI. Reproductive and endocrinological effects of benign prostatic hyperplasia and finasteride therapy in dogs. Sci Rep. 2020. doi:10.1038/s41598-020-71691-7 • PubMed

🐀 Angrimani DSR, Francischini MCP, Brito MM, Vannucchi CI. Prostatic hyperplasia: vascularization, hemodynamic and hormonal analysis of dogs treated with finasteride or orchiectomy. PLoS One. 2020. doi:10.1371/journal.pone.0234714 • PubMed

🐀 Bartolomé I, Llidó A, Darbra S, Pallarès M. Early postnatal neuroactive steroid manipulation differentially affects recognition memory and passive avoidance performance in male rats. Behav Brain Res. 2020. doi:10.1016/j.bbr.2020.112833 • PubMed

Bonde Miranda T, Garmo H, Stattin P, Robinson D. 5α-reductase inhibitors and risk of prostate cancer death. J Urol. 2020 Oct. doi:10.1097/JU.0000000000001038PubMed

📚 Busetto GM, Del Giudice F, D’Agostino D, et al. Efficacy and safety of finasteride (5 alpha-reductase inhibitor) monotherapy in patients with benign prostatic hyperplasia: a critical review of the literature. Arch Ital Urol Androl. 2020. doi:10.4081/aiua.2019.4.205 • PubMed

📚 Chen L, Zhang J, Wang L, Wang H, Chen B. The efficacy and safety of finasteride combined with topical minoxidil for androgenetic alopecia: a systematic review and meta-analysis. Aesthetic Plast Surg. 2020 Jun. doi:10.1007/s00266-020-01621-5PubMed

🐀 Chen X, Feng H, El-Kott AF, Abd-Ella EM. Origanum vulgare L. leaves extract alleviates testis and sperm damages induced by finasteride: biochemical, immunohistological and apoptosis genes based evidences [sic]. Andrologia. 2020 Dec. doi:10.1111/and.13823 • PubMed

Choi BK, Cheon K, Cho BH, Jung JW, Lee KY. Cerebral venous sinus thrombosis associated with dutasteride use. Yonsei Med J. 2020 Jun. doi:10.3349/ymj.2020.61.6.553PubMedPMC full text

🐀 Da Silva MHA, Medeiros JL Jr, Costa WS, Sampaio FJB, De Souza DB. Effects of the dutasteride and sildenafil association in the penis of a benign prostatic hyperplasia animal model. Aging Male. 2020 Dec. doi:10.1080/13685538.2019.1653839PubMedJournal full text

📚 Deng T, Duan X, He Z, Zhao Z, Zeng G. Association between 5-alpha reductase inhibitor use and the risk of depression: a meta-analysis. Urol J. 2020 Aug 23. doi:10.22037/uj.v16i7.5866 • PubMed

Dhurat R, Sharma A, Rudnicka L, et al. 5-alpha reductase inhibitors in androgenetic alopecia: shifting paradigms, current concepts, comparative efficacy, and safety. Dermatol Ther. 2020 May. doi:10.1111/dth.13379 • PubMed

Dyson TE, Cantrell MA, Lund BC. Lack of association between 5α-reductase inhibitors and depression. J Urol. 2020. doi:10.1097/JU.0000000000001079 • PubMed

Espasandín-Arias M, García-Rodiño S, Suárez-Peñaranda JM, Rodríguez-Granados MT. Photosensitivity associated with dutasteride therapy. J Dtsch Dermatol Ges. 2020 Apr. doi:10.1111/ddg.14062PubMed

Fang Q, Chen P, Du N, Nandakumar KS. Analysis of data from breast diseases treated with 5-alpha reductase inhibitors for benign prostatic hyperplasia. Clin Breast Cancer. 2019. doi:10.1016/j.clbc.2019.04.006 • PubMed

[Textbook chapter] Fraunfelder, F. Chapter 7: Hormones and drugs affecting hormonal mechanisms. Drug-Induced Ocular Side Effects. 8th Edition. Elsevier; 2020.

🐀 Gilroy ÈAM, Bartlett AJ, Gillis PL, et al. Toxicity of the pharmaceuticals finasteride and melengestrol acetate to benthic invertebrates. Environ Sci Pollut Res Int. 2020. doi:10.1007/s11356-020-10121-7 • PubMed

🐀 Golchin-Rad K, Mogheiseh A, Nazifi S, Ahrari Khafi MS, Derakhshandeh N, Abbaszadeh-Hasiri M. Changes in the serum prostatic biomarkers during the treatment of benign prostatic hyperplasia with a 5alpha-reductase inhibitor: finasteride. Top Companion Anim Med. 2020. doi:10.1016/j.tcam.2020.100405 • PubMed

🐀 Gul A, Altinay S, Kabasakal L, Yavuz A, Semercioz A, Serefoglu EC. Effect of tadalafil on penile nitric oxide synthase and corporal smooth muscle in rats under dutasteride treatment. Aging Male. 2020 Jun. doi:10.1080/13685538.2020.1739019PubMed

Gupta MA, Vujcic B, Gupta AK. Finasteride use is associated with higher odds of obstructive sleep apnea: results from the US Food and Drug Administration Adverse Events Reporting System. Skinmed. 2020. PubMed

Harrell MB, Ho K, Te AE, Kaplan SA, Chughtai B. An evaluation of the federal adverse events reporting system data on adverse effects of 5-alpha reductase inhibitors. World J Urol. 2020. doi:10.1007/s00345-020-03314-9 • PubMed

📚 Herz-Ruelas ME, Álvarez-Villalobos NA, Millán-Alanís JM, et al. Efficacy of intralesional and oral dutasteride in the treatment of androgenetic alopecia: a systematic review. Skin Appendage Disord. 2020 Nov. doi:10.1159/000510697PubMed

Ho RS. Ongoing concerns regarding finasteride for the treatment of male-pattern androgenetic alopecia. JAMA Dermatol. 2020 Nov 11. doi:10.1001/jamadermatol.2020.3384PubMed

Iamsumang W, Leerunyakul K, Suchonwanit P. Finasteride and its potential for the treatment of female pattern hair loss: evidence to date. Drug Des Devel Ther. 2020 Mar 2. doi:10.2147/DDDT.S240615PubMed

Irwig MS. Finasteride and suicide: a postmarketing case series. Dermatology. 2020. doi:10.1159/000505151 • PubMed

Kaur KK, Allahbadia G, Singh M. Post-finasteride syndrome – When will we get the courage to fight the dictating pharma industry – despite awareness of “sexual, neurological and metabolic side effects in young men for over a decade.” Arch Urol. 2020. doi:10.22259/2638-5228.0301003

Khera M, Than JK, Anaissie J, et al. Penile vascular abnormalities in young men with persistent side effects after finasteride use for the treatment of androgenic alopecia. Transl Androl Urol. 2020. doi:10.21037/tau.2020.03.21 • PubMedPMC full text

Kim JA, Choi D, Choi S, Chang J, Park SM. The association of 5α-reductase inhibitor with suicidality. Psychosom Med. 2020 Apr. doi:10.1097/PSY.0000000000000784PubMed

📚 Kim JH, Shim SR, Khandwala Y, Del Giudice F, Sorensen S, Chung BI. Risk of depression after 5 alpha reductase inhibitor medication: meta-analysis. World J Mens Health. 2020 Oct. doi:10.5534/wjmh.190046 • PubMed

Kim YJ, Tae BS, Bae JH. Cognitive function and urologic medications for lower urinary tract symptoms. Int Neurourol J. 2020 Sep. doi:10.5213/inj.2040082.041 • PubMed

Kjærulff TM, Ersbøll AK, Pukkala E, et al. Characteristics of finasteride users in comparison with nonusers: A Nordic nationwide study based on individual-level data from Denmark, Finland, and Sweden. Pharmacoepidemiol Drug Saf. 2020. doi:10.1002/pds.4947 • PubMed

Kroumpouzos G. Effects of 5-alpha reductase inhibitors on lung function: a reason for discontinuation during COVID-19 pandemic?. Dermatol Ther. 2020. doi:10.1111/dth.13535 • PubMed

La Vignera S, Aversa A, Cannarella R, et al. Pharmacological treatment of lower urinary tract symptoms in benign prostatic hyperplasia: consequences on sexual function and possible endocrine effects. Expert Opin Pharmacother. 2020. doi:10.1080/14656566.2020.1817382 • PubMed

Lee YR, Im E, Kim H, et al. Untargeted metabolomics and steroid signatures in urine of male pattern baldness patients after finasteride treatment for a year. Metabolites. 2020. doi:10.3390/metabo10040131 • PubMed

Magdaleno-Tapial J, Valenzuela-Oñate C, García-Legaz-Martínez M, et al. Angioedema-like contact dermatitis caused by mesotherapy with dutasteride. Contact Dermatitis. 2020 Sep. doi:10.1111/cod.13585PubMed

🐀 Maldarine JS, Sanches BDA, Santos VA, et al. Postnatal exposure to finasteride causes different effects on the prostate of male and female gerbils. Cell Biol Int. 2020 Jun. doi:10.1002/cbin.11328PubMed

🐀 Mendell AL, Creighton SD, Wilson HA, et al. Inhibition of 5α reductase impairs cognitive performance, alters dendritic morphology and increases tau phosphorylation in the hippocampus of male 3xTg-AD mice. Neuroscience. 2020 Mar 1. doi:10.1016/j.neuroscience.2020.01.011 • PubMed

🐀 Mohebali S, Hayati Roodbari N, Hajihosseini R, Parivar K. The effects of finasteride on the expression of DAZL, TSGA10, SCYP3, PRM2 genes during spermatogenesis in testes of NMRI mice. Eur Rev Med Pharmacol Sci. 2020. doi:10.26355/eurrev_202008_22503 • PubMed

Motofei IG, Rowland DL, Tampa M, et al. Finasteride and androgenic alopecia; from therapeutic options to medical implications. J Dermatolog Treat. 2020. doi:10.1080/09546634.2019.1595507 • PubMed

Nguyen DD, Marchese M, Cone EB, et al. Investigation of suicidality and psychological adverse events in patients treated with finasteride. JAMA Dermatol. 2020 Nov 11. doi:10.1001/jamadermatol.2020.3385PubMed

[Comment] Choi JW, Huh CH, Choi GS. Association of hair loss with suicidality and psychological adverse events vs finasteride use. JAMA Dermatol. 2021 Jun 1. doi:10.1001/jamadermatol.2021.1001PubMed

[Reply] Nguyen DD, Cone EB, Trinh QD. Association of hair loss with suicidality and psychological adverse events vs finasteride use-Reply. JAMA Dermatol. 2021 Jun 1. doi:10.1001/jamadermatol.2021.0377PubMed

🐀 Olayinka ET, Adewole KE. In vivo and in silico evaluation of the ameliorative effect of hesperidin on finasteride-induced testicular oxidative stress in Wistar rats. Toxicol Mech Methods. 2020 Oct 1. doi:10.1080/15376516.2020.1831123 • PubMed

Othonos N, Marjot T, Woods C, et al. Co-administration of 5α-reductase inhibitors worsens the adverse metabolic effects of prescribed glucocorticoids. J Clin Endocrinol Metab. 2020 Sep 1. doi:10.1210/clinem/dgaa408PubMed

Pallotti F, Senofonte G, Pelloni M, et al. Androgenetic alopecia: effects of oral finasteride on hormone profile, reproduction and sexual function. Endocrine. 2020 Feb 12. doi:10.1007/s12020-020-02219-2 • PubMed

Pereira AFJR, Coelho TOA. Post-finasteride syndrome. Anais Brasileiros de Dermatologia. 2020 Mar 25. doi:10.1016/j.abd.2020.02.001 • PubMed

Ruiz-Villaverde R, Ayen-Rodriguez A, Llamas-Molina JM. Quiz your knowledge: polycyclic annular plaques on the trunk following dutasteride treatment. Eur J Dermatol. 2020 Aug 1. doi:10.1684/ejd.2020.3823PubMed

🐀 Shalaby AM, Alabiad MA, El Shaer DF. Resveratrol ameliorates the seminiferous tubules damages induced by finasteride in adult male rats. Microsc Microanal. 2020 Oct 5. doi:10.1017/S1431927620024514 • PubMed

Shin YK, Lee GW, Kang SW, Kim SJ, Kim AY. Macular abnormalities associated with 5α-reductase inhibitor. JAMA Ophthalmol. 2020 Jul 1. doi:10.1001/jamaophthalmol.2020.1279 • PubMed

[Letter] Burgos-Blasco B, Burgos-Blasco P. Macular abnormalities associated with 5α-reductase inhibitor. JAMA Ophthalmol. 2021 Feb 1. 10.1001/jamaophthalmol.2020.5768PubMed

[Reply] Shin YK, Kang SW. Macular abnormalities associated with 5α-reductase inhibitor-Reply. JAMA Ophthalmol. 2021 Feb 1. 10.1001/jamaophthalmol.2020.5774PubMed

Suchonwanit P, Iamsumang W, Leerunyakul K. Topical finasteride for the treatment of male androgenetic alopecia and female pattern hair loss: a review of the current literature. J Dermatolog Treat. 2020. doi:10.1080/09546634.2020.1782324 • PubMed

Traish AM. Health risks associated with long-term finasteride and dutasteride use: It’s time to sound the alarm. World J Mens Health. 2020 Jul. doi:10.5534/wjmh.200012 • PubMedPMC full text

[Letter] Sirufo MM, Ginaldi L, De Martinis M. Bone health risks associated with finasteride and dutasteride long-term use. World J Mens Health. 2020 Nov 26. 10.5534/wjmh.200138PubMed

Traish AM. Post-finasteride syndrome: a surmountable challenge for clinicians. Fertil Steril. 2020. doi:10.1016/j.fertnstert.2019.11.030 • PubMed

Vañó-Galván S, Saceda-Corralo D, Moreno-Arrones OM, et al. Effectiveness and safety of oral dutasteride for male androgenetic alopecia in real clinical practice: a descriptive monocentric study. Dermatol Ther. 2020 Jan. doi:10.1111/dth.13182PubMed

📚 Wang L, Lei Y, Gao Y, Cui D, Tang Q, Li R, Wang D, Chen Y, Zhang B, Wang H. Association of finasteride with prostate cancer: a systematic review and meta-analysis. Medicine (Baltimore). 2020 Apr. doi:10.1097/MD.0000000000019486 • PubMedPMC full text

Xu W, Schiffer L, Qadir MMF, et al. Intracrine testosterone activation in human pancreatic β-cells stimulates insulin secretion. Diabetes. 2020 Nov. doi:10.2337/db20-0228PubMedPMC full text

📚 Zhou Z, Cui Y, Wu J, Jin H. Efficacy and safety of dutasteride compared with finasteride in treating males with benign prostatic hyperplasia: a meta-analysis of randomized controlled trials. Exp Ther Med. 2020. doi:10.3892/etm.2020.8851 • PubMed

2020 abstracts

🧬 Ihentuge C, Csoka A. Epigenetic effects of finasteride on human Leydig cells. The FASEB Journal. Supplement: Experimental Biology 2020 Meeting Abstracts. 2020;S1. doi:10.1096/fasebj.2020.34.s1.03823

Rivera Mirabal J, Than J, Annaisie J, et al. 124 The persistent effects of 5α-reductase inhibitors used in the treatment of androgenic alopecia on men’s health. J Sex Med. 2020;Suppl. doi:10.1016/j.jsxm.2019.11.070


↑ back to top

Alcántara Montero A, Müller-Arteaga C. 5-alpha reductase inhibitors: new evidences on benefits and harms beyond benign prostatic hyperplasia. Inhibidores de la 5-alfa reductasa: nuevas evidencias sobre los beneficios y los daños más allá de la hiperplasia benigna de próstata. Actas Urol Esp. 2019. doi:10.1016/j.acuro.2018.05.003 • PubMed

🐀 Alkahtane AA, Albasher G, Al-Sultan NK, et al. Long-term treatment with finasteride induces apoptosis and pathological changes in female mice. Hum Exp Toxicol. 2019. doi:10.1177/0960327119842195 • PubMed

Andy G, John M, Mirna S, et al. Controversies in the treatment of androgenetic alopecia: The history of finasteride. Dermatol Ther. 2019. doi:10.1111/dth.12647 • PubMed

🐀 Baig MS, Kolasa-Wołosiuk A, Pilutin A, et al. Finasteride-induced inhibition of 5α-reductase type 2 could lead to kidney damage-animal, experimental study. Int J Environ Res Public Health. 2019. doi:10.3390/ijerph16101726 • PubMed

🐀 Bartolomé I, Llidó A, Darbra S, Pallarès M. Early postnatal allopregnanolone levels alteration and adult behavioral disruption in rats: implication for drug abuse. Neurobiol Stress. 2019. doi:10.1016/j.ynstr.2019.100208 • PubMed

Bortnick EM, Simma-Chiang V, Kaplan SA. Long-term consequences of medical therapy for benign prostatic hyperplasia. Rev Urol. 2019. PubMedPMC full text

Catalano A, Martino G, Bellone F, et al. Neuropsychological assessment in elderly men with benign prostatic hyperplasia treated with dutasteride. Clin Drug Investig. 2019 Jan. Erratum in: Clin Drug Investig. 2018 Nov 26. doi:10.1007/s40261-018-0720-7 • PubMed

Coskuner ER, Ozkan B, Culha MG. Sexual problems of men with androgenic alopecia treated with 5-alpha reductase inhibitors. Sex Med Rev. 2019. doi:10.1016/j.sxmr.2018.07.003 • PubMed

🐀 Diviccaro S, Giatti S, Borgo F, et al. Treatment of male rats with finasteride, an inhibitor of 5alpha-reductase enzyme, induces long-lasting effects on depressive-like behavior, hippocampal neurogenesis, neuroinflammation and gut microbiota composition. Psychoneuroendocrinology. 2019. doi:10.1016/j.psyneuen.2018.09.021PubMed

Diviccaro S, Melcangi RC, Giatti S. Post-finasteride syndrome: an emerging clinical problem. Neurobiol Stress. 2019. doi:10.1016/j.ynstr.2019.100209 • PubMed

🐀 Fanni S, Scheggi S, Rossi F, et al. 5alpha-reductase inhibitors dampen L-DOPA-induced dyskinesia via normalization of dopamine D1-receptor signaling pathway and D1-D3 receptor interaction. Neurobiol Dis. 2019. doi:10.1016/j.nbd.2018.09.018 • PubMed

🧬 Ghassemi M, Ghaffarpour GH, Ghods S. The effect of GGC and CAG repeat polymorphisms on the androgen receptor gene in response to finasteride therapy in men with androgenetic alopecia. J Res Med Sci. 2019. doi:10.4103/jrms.JRMS_27_19 • PubMed

🐀 Godar SC, Cadeddu R, Floris G, et al. The steroidogenesis inhibitor finasteride reduces the response to both stressful and rewarding stimuli. Biomolecules. 2019. doi:10.3390/biom9110749 • PubMed

Gray SL, Semla TP. Post-finasteride syndrome. BMJ. 2019. doi:10.1136/bmj.l5047 • PubMed

Haber RS, Gupta AK, Epstein E, Carviel JL, Foley KA. Finasteride for androgenetic alopecia is not associated with sexual dysfunction: a survey-based, single-centre, controlled study. J Eur Acad Dermatol Venereol. 2019. doi:10.1111/jdv.15548PubMed

Kaczmarek IA, Prost ME, Wasyluk J. Clinical risk factors associated with intraoperative floppy iris syndrome: a prospective study. Int Ophthalmol. 2019. doi:10.1007/s10792-018-0840-3 • PubMed

🐀 Kilic S, Kolukcu E, Erdemir F, Benli I, Arici A. The effects of oral 5-alpha reductase inhibitors on penile intracavernosal pressures and penile morphology in rat model. Urology J. 2019. doi:10.22037/uj.v0i0.4164 • PubMed

Kjærulff TM, Ersbøll AK, Green A, et al. Finasteride use and risk of male breast cancer: a case-control study using individual-level registry data from Denmark, Finland, and Sweden. Cancer Epidemiol Biomarkers Prev. 2019 May. doi:10.1158/1055-9965.EPI-18-0904PubMed

🐀 🧬 Kolasa-Wołosiuk A, Tarnowski M, Baranowska-Bosiacka I, Chlubek D, Wiszniewska B. Antioxidant enzyme expression of mRNA and protein in the epididymis of finasteride-treated male rat offspring during postnatal development. Arch Med Sci. 2019 May. doi:10.5114/aoms.2017.68528PubMedPMC full text

Kuno T, Uchida Y, Usami T, et al. A young male of [sic] hemorrhagic cerebral infarction associated with finasteride and minoxidil. Nosotchu. 2019 Nov;42(4). Japanese. doi:10.3995/jstroke.10722ResearchGate • Automated translation to English (unofficial)

📚 Lee S, Lee YB, Choe SJ, Lee WS. Adverse sexual effects of treatment with finasteride or dutasteride for male androgenetic alopecia: a systematic review and meta-analysis. Acta Derm Venereol. 2019. doi:10.2340/00015555-3035 • PubMed

Lee SG, Park PJ, Lee SR, et al. Influence of postoperative finasteride therapy on recurrence of gynecomastia after mastectomy in men taking finasteride for alopecia. Am J Mens Health. 2019 Sep-Oct. doi:10.1177/1557988319871423 • PubMed

Maksym RB, Kajdy A, Rabijewski M. Post-finasteride syndrome – does it really exist?. Aging Male. 2019. doi:10.1080/13685538.2018.1548589 • PubMed

🐀 Maldarine JS, Sanches BDA, Cabral ÁS, et al. Prenatal exposure to finasteride promotes sex-specific changes in gerbil prostate development. Reprod Fertil Dev. 2019. doi:10.1071/RD19106 • PubMed

Marks DH, Prasad S, De Souza B, Burns LJ, Senna MM. Topical antiandrogen therapies for androgenetic alopecia and acne vulgaris. Am J Clin Dermatol. 2019 Dec 12. doi:10.1007/s40257-019-00493-z • PubMed

🧬 Melcangi RC, Casarini L, Marino M, et al. Altered methylation pattern of the SRD5A2 gene in the cerebrospinal fluid of post-finasteride patients: a pilot study. Endocr Connect. 2019. doi:10.1530/EC-19-0199 • PubMed

Muderrisoglu AE, Becher KF, Madersbacher S, Michel MC. Cognitive and mood side effects of lower urinary tract medication. Expert Opin Drug Saf. 2019 Oct. doi:10.1080/14740338.2019.1652269PubMed

🐀 Sasibhushana RB, Shankaranarayana Rao BS, Srikumar BN. Repeated finasteride administration induces depression-like behavior in adult male rats. Behav Brain Res. 2019. doi:10.1016/j.bbr.2019.03.006 • PubMed

Shin YS, Karna KK, Choi BR, Park JK. Finasteride and erectile dysfunction in patients with benign prostatic hyperplasia or male androgenetic alopecia. World J Mens Health. 2019. doi:10.5534/wjmh.180029PubMed

🐀 Sung HH, Yu J, Kang SJ, et al. Persistent erectile dysfunction after discontinuation of 5-alpha reductase inhibitor therapy in rats depending on the duration of treatment. World J Mens Health. 2019. doi:10.5534/wjmh.180082 • PubMed

📚 Traish AM, Krakowsky Y, Doros G, Morgentaler A. Do 5α-reductase inhibitors raise circulating serum testosterone levels? a comprehensive review and meta-analysis to explaining paradoxical results. Sex Med Rev. 2019. doi:10.1016/j.sxmr.2018.06.002PubMed

Trüeb RM, Régnier A, Dutra Rezende H, Gavazzoni Dias MFR. Post-finasteride syndrome: an induced delusional disorder with the potential of a mass psychogenic illness? Skin Appendage Disord. 2019. doi:10.1159/000497362PubMed

Wei L, Lai EC, Kao-Yang YH, Walker BR, MacDonald TM, Andrew R. Incidence of type 2 diabetes mellitus in men receiving steroid 5α-reductase inhibitors: population based cohort study. BMJ. 2019. doi:10.1136/bmj.l1204 • PubMedPMC full text

Yanagisawa M, Fujimaki H, Takeda A, Nemoto M, Sugimoto T, Sato A. Long-term (10-year) efficacy of finasteride in 523 Japanese men with androgenetic alopecia. Clin Res Trials. 2019;5:1-5. doi:10.15761/CRT.1000273

📚 Zakhem GA, Goldberg JE, Motosko CC, Cohen BE, Ho RS. Sexual dysfunction in men taking systemic dermatologic medication: a systematic review. J Am Acad Dermatol. 2019. doi:10.1016/j.jaad.2019.03.043 • PubMed

📚 Zakhem GA, Motosko CC, Mu EW, Ho RS. Infertility and teratogenicity after paternal exposure to systemic dermatologic medications: a systematic review. J Am Acad Dermatol. 2019 Apr. doi:10.1016/j.jaad.2018.09.031PubMed

📚 Zhou Z, Cui Y, Wu J, Ding R, Cai T, Gao Z. Meta-analysis of the efficacy and safety of combination of tamsulosin plus dutasteride compared with tamsulosin monotherapy in treating benign prostatic hyperplasia. BMC Urol. 2019 Mar 11. doi:10.1186/s12894-019-0446-8PubMedPMC full text

📚 Zhou Z, Song S, Gao Z, Wu J, Ma J, Cui Y. The efficacy and safety of dutasteride compared with finasteride in treating men with androgenetic alopecia: a systematic review and meta-analysis. Clin Interv Aging. 2019. doi:10.2147/CIA.S192435PubMed


↑ back to top

Almohanna HM, Perper M, Tosti A. Safety concerns when using novel medications to treat alopecia. Expert Opin Drug Saf. 2018 Nov;17(11):1115-1128. doi:10.1080/14740338.2018.1533549 | PubMed

AlSaad D, Lee BH, Al-Obaidly S. Finasteride use during pregnancy and early neonatal outcome: a case report. Int J Clin Pharm. 2018;40(4):803-805. doi:10.1007/s11096-018-0661-5 | PubMed

Andrade C. Why odds ratios can be tricky statistics: the case of finasteride, dutasteride, and sexual dysfunction. J Clin Psychiatry. 2018;79(6). doi:10.4088/JCP.18f12641 | PubMed

Antoniou T, Macdonald EM, Yao Z, et al. A population-based study of the risk of osteoporosis and fracture with dutasteride and finasteride. BMC Musculoskelet Disord. 2018;19(1):160. doi:10.1186/s12891-018-2076-9 | PubMed

[⚠️ Co-author KT McVary retained by Merck as litigation expert] Baas WR, Butcher MJ, Lwin A, et al. A review of the FAERS data on 5-alpha reductase inhibitors: implications for postfinasteride syndrome. Urology. 2018 Oct;120:143-149. doi:10.1016/j.urology.2018.06.022 | PubMed

🐀 Da Silva MHA, Costa WS, Sampaio FJB, De Souza DB. The corpus cavernosum after treatment with dutasteride or finasteride: a histomorphometric study in a benign prostatic hyperplasia rodent model. Asian J Androl. 2018;20(5):505–510. doi:10.4103/aja.aja_28_18 | PubMed | PMC full text

Ganzer CA, Jacobs AR. Emotional consequences of finasteride: fool’s gold. Am J Mens Health. 2018;12(1):90–95. doi:10.1177/1557988316631624 | PubMed

Giatti S, Diviccaro S, Panzica G, Melcangi RC. Post-finasteride syndrome and post-SSRI sexual dysfunction: two sides of the same coin? Endocrine. 2018;61(2):180-193. doi:10.1007/s12020-018-1593-5 | PubMed

Gupta AK, Carviel J, Gupta MA, Shear NH. Assessing dutasteride-associated sexual dysfunction using the U.S. Food and Drug Administration Adverse Event Reporting System. J Eur Acad Dermatol Venereol. 2018;32(8):1373-1376. doi:10.1111/jdv.14728 | PubMed

Healy D, Le Noury J, Mangin D. Enduring sexual dysfunction after treatment with antidepressants, 5α-reductase inhibitors and isotretinoin: 300 cases. Int J Risk Saf Med. 2018;29(3-4):125-134. doi:10.3233/JRS-180744 | PubMed

📚 Kim JH, Baek MJ, Sun HY, et al. Efficacy and safety of 5 alpha-reductase inhibitor monotherapy in patients with benign prostatic hyperplasia: a meta-analysis. PLoS One. 2018;13(10):e0203479. Published 2018 Oct 3. doi:10.1371/journal.pone.0203479 | PubMed

Kosilov K, Kuzina I, Kuznetsov V, . The risk of sexual dysfunction and effectiveness of treatment of benign prostatic hyperplasia with severe lower urinary tract dysfunction with combination of dutasteride and solifenacin. J Sex Med. 2018 Nov. doi:10.1016/j.jsxm.2018.09.011 | PubMed

Lee JY, Cho KS. Effects of 5-alpha reductase inhibitors: new insights on benefits and harms. Curr Opin Urol. 2018;28(3):288–293. doi:10.1097/MOU.0000000000000497 | PubMed

📚 Lee SW, Juhasz M, Mobasher P, Ekelem C, Mesinkovska NA. A systematic review of topical finasteride in the treatment of androgenetic alopecia in men and women. J Drugs Dermatol. 2018;17(4):457–463. Journal site | PubMed

🐀 Li L, Kang YX, Ji XM, et al. Finasteride inhibited brain dopaminergic system and open-field behaviors in adolescent male rats. CNS Neurosci Ther. 2018;24(2):115-125. doi:10.1111/cns.12781

🐀 Maurice-Gélinas C, Deslauriers J, Monpays C, Sarret P, Grignon S. The 5α-reductase inhibitor finasteride increases suicide-related aggressive behaviors and blocks clozapine-induced beneficial effects in an animal model of schizophrenia. Physiol Behav. 2018;191:65–72. doi:10.1016/j.physbeh.2018.03.036 | PubMed

McVary KT, Rogers T, Mahon J, Gupta NK. Is sexual function better preserved after water vapor thermal therapy or medical therapy for lower urinary tract symptoms due to benign prostatic hyperplasia?. J Sex Med. 2018;15(12):1728–1738. doi:10.1016/j.jsxm.2018.10.006 | PubMed

[Comment] Kaplan SA. Re: Is sexual function better preserved after water vapor thermal therapy or medical therapy for lower urinary tract symptoms due to benign prostatic hyperplasia?. J Urol. 2020;101097JU0000000000000985. doi:10.1097/JU.0000000000000985

Mervis JS, Borda LJ, Miteva M. “Post-finasteride syndrome”: what to tell our female patients? Br J Dermatol. 2018;179(3):785-786. doi:10.1111/bjd.16658 | PubMed

Motofei IG, Rowland DL, Baconi DL, et al. Androgenetic alopecia; drug safety and therapeutic strategies. Expert Opin Drug Saf. 2018 Apr;17(4):407-412. doi:10.1080/14740338.2018.1430765 | PubMed

[⚠️ Authors employed by GSK] [Letter] Ong G, Manyak M, Lulic Z. Letter to the Editor: androgenetic alopecia; drug safety and therapeutic strategies. Expert Opin Drug Saf. 2018 Jun;17(6):651-652. doi:10.1080/14740338.2018.1470744 | PubMed

Rezende HD, Dias MFRG, Trüeb RM. A comment on the post-finasteride syndrome. Int J Trichology. 2018;10(6):255-261. doi:10.4103/ijt.ijt_61_18 | PMC full text

Roehrborn CG, Manyak MJ, Palacios-Moreno JM, et al. A prospective randomised placebo-controlled study of the impact of dutasteride/tamsulosin combination therapy on sexual function domains in sexually active men with lower urinary tract symptoms (LUTS) secondary to benign prostatic hyperplasia (BPH). BJU Int. 2018 Apr;121(4):647-658. doi:10.1111/bju.14057 | PubMed

Rowland DL, Motofei IG, Păunică I, et al. Androgenic alopecia; the risk–benefit ratio of finasteride. J Mind Med Sci. 2018;5(1):1–6. doi:10.22543/7674.51.P16 | Full text (PDF)

Said MA, Mehta A. The impact of 5α-reductase inhibitor use for male pattern hair loss on men’s health. Curr Urol Rep. 2018;19(8):65. doi:10.1007/s11934-018-0814-z | PubMed

Schmutz JL. Dépression et idées suicidaires avec le finastéride [Depression and suicidal thoughts associated with finasteride]. Ann Dermatol Venereol. 2018;145(2):155–156. doi:10.1016/j.annder.2018.01.006 | PubMed

Sorbellini E, Pinto D, Marzani B, Rinaldi F. Drug treatment for androgenetic alopecia: first Italian questionnaire survey on what dermatologists think about finasteride. Dermatol Ther (Heidelb). 2018;8(2):259-267. doi:10.1007/s13555-018-0233-6

🐀 🧬 Sun S, Wang YC, Guo K, DU J, Zhou HJ, Ren AJ. [Finasteride inhibits microvascular density and VEGF expression in the seminal vesicle of rats]. Zhonghua Nan Ke Xue. 2018 May;24(5):387-392. Chinese. PubMed

Than JK, Rodriguez K, Khera M. Post-finasteride syndrome: a review of current literature. Curr Sex Health Rep. 2018;10:152-157. doi:10.1007/s11930-018-0163-4

🧬 Traish, AM. The post-finasteride syndrome: clinical manifestation of drug-induced epigenetics due to endocrine disruption. Curr Sex Health Rep. 2018;10:88–103. doi:10.1007/s11930-018-0161-6

[⚠️ Funded by GSK, maker of Avodart (dutasteride)] Tsai TF, Choi GS, Kim BJ, et al. Prospective randomized study of sexual function in men taking dutasteride for the treatment of androgenetic alopecia. J Dermatol. 2018 Jul. doi:10.1111/1346-8138.14329 | PubMed | PMC full text

Walf AA, Kaurejo S, Frye CA. Research brief: self-reports of a constellation of persistent antiandrogenic, estrogenic, physical, and psychological effects of finasteride usage among men. Am J Mens Health. 2018;12(4):900-906. doi:10.1177/1557988317750989 | PubMed

Welk B, McArthur E, Ordon M, Dirk J, Dixon S, Garg AX. Risk of rhabdomyolysis from 5-α reductase inhibitors. Pharmacoepidemiol Drug Saf. 2018 Mar;27(3):351-355. doi:10.1002/pds.4383 | PubMed

Zhang Y, Xu J, Jing J, Wu X, Lv Z. Serum levels of androgen-associated hormones are correlated with curative effect in androgenic alopecia in young men. Med Sci Monit. 2018;24:7770-7777. doi:10.12659/MSM.913116

2018 abstracts

Gupta MA, Vujcic B, Sheridan AD, Gupta AK. 0917 Finasteride is associated with a higher odds of obstructive sleep apnea (OSA): results from the US FDA Adverse Events Reporting System (FAERS). Sleep. 2018 Apr;41(Issue suppl_1):A340–A341. doi:10.1093/sleep/zsy061.916

Nguyen LH, Makino A, Namkoong P, Yiannakou Y, Narain K. Finasteride induced clinical ocular toxicity (ARVO Annual Meeting Abstract). Investigative Ophthalmology & Visual Science. 2018 Jul;59(9):2655. Abstract | Poster | Letter from K. Narain on findings


↑ back to top

Arif T, Dorjay K, Adil M, Sami M. Dutasteride in androgenetic alopecia: an update. Curr Clin Pharmacol. 2017;12(1):31–35. doi:10.2174/1574884712666170310111125 | PubMed

🧬 Cauci S, Chiriacò G, Cecchin E, et al. Androgen receptor (AR) gene (CAG)n and (GGN)n length polymorphisms and symptoms in young males with long-lasting adverse effects after finasteride use against androgenic alopecia. Sex Med. 2017 Mar;5(1):e61-e71. doi:10.1016/j.esxm.2016.11.001 | PubMed | PMC full text

📚 Corona G, Tirabassi G, Santi D, et al. Sexual dysfunction in subjects treated with inhibitors of 5α-reductase for benign prostatic hyperplasia: a comprehensive review and meta-analysis. Andrology. 2017;5(4):671-678. doi:10.1111/andr.12353 | PubMed

🐀 Cumberland AL, Palliser HK, Crombie GK, Walker DW, Hirst JJ. Increased anxiety-like phenotype in female guinea pigs following reduced neurosteroid exposure in utero. Int J Dev Neurosci. 2017;58:50–58. doi:10.1016/j.ijdevneu.2017.02.001 | PubMed

Drobnis EZ, Nangia AK. 5α-reductase inhibitors (5ARIs) and male reproduction. Adv Exp Med Biol. 2017;1034:59–61. doi:10.1007/978-3-319-69535-8_7 | PubMed

Enatsu N, Chiba K, Sumii K, et al. Dutasteride-mediated morphological changes in the genitourinary tract associated with altered expression patterns of the androgen and estrogen receptors in male rats. Andrology. 2017 Mar;5(2):347-353. doi:10.1111/andr.12297 | PubMed

📚 Fertig RM, Gamret AC, Darwin E, Gaudi S. Sexual side effects of 5-α-reductase inhibitors finasteride and dutasteride: A comprehensive review. Dermatol Online J. 2017;23(11). Journal site | PubMed

Fouda AM, Bazeed AM. Hematuria and hematospermia associated with the use of finasteride for the treatment of androgenic alopecia: a case report. Drug Saf Case Rep. 2017 Oct 31;4(1):14. doi:10.1007/s40800-017-0059-7. PubMed | PMC full text

Gandhi J, Weissbart SJ, Smith NL, et al. The impact and management of sexual dysfunction secondary to pharmacological therapy of benign prostatic hyperplasia. Transl Androl Urol. 2017 Apr;6(2):295-304. doi:10.21037/tau.2017.03.57 | PubMed

🐀 🧬 García-García M, Sánchez-Hernández M, García-Hernández MP, García-Ayala A, Chaves-Pozo E. Role of 5α-dihydrotestosterone in testicular development of gilthead seabream following finasteride administration. J Steroid Biochem Mol Biol. 2017;174:48-55. doi:10.1016/j.jsbmb.2017.07.024 | PubMed

Gupta AK, Carviel J, MacLeod MA, Shear N. Assessing finasteride-associated sexual dysfunction using the FAERS database. J Eur Acad Dermatol Venereol. 2017;31(6):1069-1075. doi:10.1111/jdv.14223 | PubMed

Hagberg KW, Divan HA, Fang SC, Nickel JC, Jick SS. Risk of gynecomastia and breast cancer associated with the use of 5-alpha reductase inhibitors for benign prostatic hyperplasia. Clin Epidemiol. 2017;9:83‐91. doi:10.2147/CLEP.S124674 | PubMed

Hagberg KW, Divan HA, Nickel JC, Jick SS. Risk of incident antidepressant-treated depression associated with use of 5α-reductase inhibitors compared with use of α-blockers in men with benign prostatic hyperplasia: a population-based study using the Clinical Practice Research Datalink. Pharmacotherapy. 2017;37(5):517‐527. doi:10.1002/phar.1925 | PubMed

📚 Jun JEJ, Kinkade A, Tung ACH, Tejani AM. 5α-reductase inhibitors for treatment of benign prostatic hyperplasia: a systematic review and meta-analysis. Can J Hosp Pharm. 2017;70(2):113-119. doi:10.4212/cjhp.v70i2.1643 | PubMed

Kiguradze T, Temps WH, Yarnold PR, et al. Persistent erectile dysfunction in men exposed to the 5α-reductase inhibitors, finasteride, or dutasteride. PeerJ. 2017;5:e3020. doi:10.7717/peerj.3020 | PubMed

Kuhl, H., Wiegratz, I. Das post-finasterid-Syndrom. Gynäkologische Endokrinologie. 2017;15:153–163. doi:10.1007/s10304-017-0126-2

🐀 Li K, Zhang C, Yang Z, Wang Y, Si H. Evaluation of a novel dry eye model induced by oral administration of finasteride. Mol Med Rep. 2017;16(6):8763–8770. doi:10.3892/mmr.2017.7754 | PubMed

🐀 Litim N, Morissette M, Caruso D, Melcangi RC, Di Paolo T. Effect of the 5α-reductase enzyme inhibitor dutasteride in the brain of intact and parkinsonian mice. J Steroid Biochem Mol Biol. 2017;174:242‐256. doi:10.1016/j.jsbmb.2017.09.021 | PubMed

Melcangi RC, Santi D, Spezzano R, et al. Neuroactive steroid levels and psychiatric and andrological features in post-finasteride patients. J Steroid Biochem Mol Biol. 2017;171:229-235. doi:10.1016/j.jsbmb.2017.04.003 | PubMed

Motofei IG, Rowland DL, Georgescu SR, et al. Post-finasteride adverse effects in male androgenic alopecia: a case report of vitiligo. Skin Pharmacol Physiol. 2017;30(1):42-45. doi:10.1159/000455972 | PubMed

Motofei IG, Rowland DL, Manea M, Georgescu SR, Păunică I, Sinescu I. Safety profile of finasteride: distribution of adverse effects according to structural and informational dichotomies of the mind/brain. Clin Drug Investig. 2017;37(6):511-517. doi:10.1007/s40261-017-0501-8 | PubMed

Shanshanwal SJ, Dhurat RS. Superiority of dutasteride over finasteride in hair regrowth and reversal of miniaturization in men with androgenetic alopecia: a randomized controlled open-label, evaluator-blinded study. Indian J Dermatol Venereol Leprol. 2017;83(1):47-54. doi:10.4103/0378-6323.188652

🐀 Soni KK, Shin YS, Choi BR, et al. Protective effect of DA-9401 in finasteride-induced apoptosis in rat testis: inositol requiring kinase 1 and c-Jun N-terminal kinase pathway. Drug Des Devel Ther. 2017;11:2969-2979. doi:10.2147/DDDT.S140543 | PubMed

Teichert M, van Puijenbroek E, Stricker BH. Contraindicated use of 5-alpha-reductase inhibitors in women. Br J Clin Pharmacol. 2017;83(2):429-431. doi:10.1111/bcp.13118 | PubMed

Traish AM. Negative impact of testosterone deficiency and 5α-reductase inhibitors therapy on metabolic and sexual function in men. Adv Exp Med Biol. 2017;1043:473-526. doi:10.1007/978-3-319-70178-3_22 | PubMed

Traish A, Haider KS, Doros G, Haider A. Long-term dutasteride therapy in men with benign prostatic hyperplasia alters glucose and lipid profiles and increases severity of erectile dysfunction. Horm Mol Biol Clin Investig. 2017;30(3). doi:10.1515/hmbci-2017-0015 | PubMed

Trüeb RM. Discriminating in favour of or against men with increased risk of finasteride-related side effects? Exp Dermatol. 2017;26(6):527-528. doi:10.1111/exd.13155 | PubMed

Voznesensky I, Shaw E, DeLay KJ, Yafi F, Hellstrom, WJG. Benign prostatic hyperplasia treatment options and their effects on sexual function. Sexual Medicine Reviews. Jan 2017;5(1):87-102. doi:10.1016/j.sxmr.2016.05.006

Welk B, McArthur E, Ordon M, Anderson KK, Hayward J, Dixon S. Association of suicidality and depression with 5α-reductase inhibitors. JAMA Intern Med. 2017;177(5):683–691. doi:10.1001/jamainternmed.2017.0089 | PubMed

Welk B, McArthur E, Ordon M, Morrow SA, Hayward J, Dixon S. The risk of dementia with the use of 5 alpha reductase inhibitors. J Neurol Sci. 2017;379:109-111. doi:10.1016/j.jns.2017.05.064 | PubMed

2017 abstracts

Ibarra Vilar P, Marín Pérez A, Hernández Peñalver AI, et al. Genitales ambiguos tras toma de finasteride [Ambiguous genitalia after taking finasteride]. Presented at: XXVII Reunión de la Sociedad Ginecológica Murciana: Laparoscopia ginecológica. March 4, 2017; Hospital Comarcal del Noroeste, Caravaca de la Cruz, Spain. Communication (PDF)


↑ back to top

Arias-Santiago S, Camacho-Martínez FM. Adverse effects of 5-alpha reductase inhibitor therapy in men with androgenetic alopecia: Is there cause for concern? [Efectos adversos de los inhibidores de la 5-alfa-reductasa en la alopecia androgenética masculina ¿Hay por qué preocuparse?]. Actas Dermosifiliogr. 2016;107(9):709–711. doi:10.1016/ | PubMed

🧬 Basaria S, Jasuja R, Huang G, et al. Characteristics of men who report persistent sexual symptoms after finasteride use for hair loss. J Clin Endocrinol Metab. 2016;101(12):4669-4680. doi:10.1210/jc.2016-2726 | PubMed

Santmann J. Letter to the Editor: “Characteristics of men who report persistent sexual symptoms after finasteride use for hair loss.” J Clin Endocrinol Metab. 2017;102(6):2117-2118. doi:10.1210/jc.2016-3491

Bhasin S, Stern E, Basaria S. Response to Letter: “Characteristics of men who report persistent sexual symptoms after finasteride use for hair loss.” J Clin Endocrinol Metab. 2017;102(6):2119-2120. doi:10.1210/jc.2016-3682

Cakir OO, Serefoglu EC. Post-finasteride syndrome: an underestimated phenomenon. Urol Androl Open J. 2017;1(1):e3-e4. doi:10.17140/UAOJ-1-e002 | Full text from journal

Carreño-Orellana N, Moll-Manzur C, Carrasco-Zuber JE, Álvarez-Véliz S, Berroeta-Mauriziano D, Porras-Kusmanic N. Efectos adversos de finasteride: mitos y realidades. Una revisión actualizada [Finasteride adverse effects: an update]. Rev Med Chil. 2016;144(12):1584‐1590. doi:10.4067/S0034-98872016001200010 | PubMed

Chatziralli IP, Peponis V, Parikakis E, Maniatea A, Patsea E, Mitropoulos P. Risk factors for intraoperative floppy iris syndrome: a prospective study. Eye (Lond). 2016 Aug;30(8):1039-44. doi:10.1038/eye.2016.122 | PubMed | PMC full text

Chatziralli IP, Sergentanis TN, Papazisis L, Moschos MM. Risk factors for intraoperative floppy iris syndrome: a retrospective study. Acta Ophthalmol. 2012 Mar;90(2):e152-3. doi:10.1111/j.1755-3768.2011.02132.x | PubMed

Chiriacò G, Cauci S, Mazzon G, Trombetta C. An observational retrospective evaluation of 79 young men with long-term adverse effects after use of finasteride against androgenetic alopecia. Andrology. 2016;4(2):245-250. doi:10.1111/andr.12147 | PubMed | Free full text (Wiley)

🐀 Corbin CJ, Legacki EL, Ball BA, Scoggin KE, Stanley SD, Conley AJ. Equine 5α-reductase activity and expression in epididymis. J Endocrinol. 2016;231(1):23-33. doi:10.1530/JOE-16-0175 | PubMed

📚 Favilla V, Russo GI, Privitera S, et al. Impact of combination therapy 5-alpha reductase inhibitors (5-ARI) plus alpha-blockers (AB) on erectile dysfunction and decrease of libido in patients with LUTS/BPH: a systematic review with meta-analysis. Aging Male. 2016;19(3):175-181. doi:10.1080/13685538.2016.1195361 | PubMed

Fertig R, Shapiro J, Bergfeld W, Tosti A. Investigation of the plausibility of 5-alpha-reductase inhibitor syndrome. Skin Appendage Disord. 2016;2(3-4):120-129. doi:10.1159/000450617 | PubMed

Füllhase C, Schneider MP. 5-alpha-reductase inhibitors and combination therapy. Urol Clin North Am. 2016;43(3):325-336. doi:10.1016/j.ucl.2016.04.003 | PubMed

Garreton AS, Valzacchi GR, Layus O. Post-finasteride syndrome: about 2 cases and review of the literature. Andrology-Open Access. 2016;5(2):170. doi:10.4172/2472-1212.1000170 | Journal site

🐀 Giatti S, Foglio B, Romano S, et al. Effects of subchronic finasteride treatment and withdrawal on neuroactive steroid levels and their receptors in the male rat brain. Neuroendocrinology. 2016;103(6):746-757. doi:10.1159/000442982 | PubMed

Guo M, Heran B, Flannigan R, Kezouh A, Etminan M. Persistent sexual dysfunction with finasteride 1 mg taken for hair loss. Pharmacotherapy. 2016;36(11):1180-1184. doi:10.1002/phar.1837 | PubMed

Gupta AK, Sharma N, Shukla P. Atypical post-finasteride syndrome: a pharmacological riddle. Indian J Pharmacol. 2016;48(3):316–317. doi:10.4103/0253-7613.182898 | PubMed

Hagberg KW, Divan HA, Persson R, Nickel JC, Jick SS. Risk of erectile dysfunction associated with use of 5-α reductase inhibitors for benign prostatic hyperplasia or alopecia: population based studies using the Clinical Practice Research Datalink. BMJ. 2016;354:i4823. doi:10.1136/bmj.i4823 | PubMed

[Comment] Gupta NK, McVary KT. Re: Risk of erectile dysfunction associated with use of 5α-reductase inhibitors for benign prostatic hyperplasia or alopecia: population based studies using the Clinical Practice Research Datalink. Eur Urol. 2017;72(2):317–318. doi:10.1016/j.eururo.2017.03.043 | PubMed

Hazlehurst JM, Oprescu AI, Nikolaou N, et al. Dual-5α-reductase inhibition promotes hepatic lipid accumulation in man. J Clin Endocrinol Metab. 2016;101(1):103–113. doi:10.1210/jc.2015-2928 | PubMed

📚 Hirshburg JM, Kelsey PA, Therrien CA, Gavino AC, Reichenberg JS. Adverse effects and safety of 5-alpha reductase inhibitors (finasteride, dutasteride): a systematic review. J Clin Aesthet Dermatol. 2016;9(7):56-62. PubMed | PMC full text

Kaplan SA, Lee JY, Meehan AG, Kusek JW. time course of incident adverse experiences associated with doxazosin, finasteride and combination therapy in men with benign prostatic hyperplasia: the MTOPS trial. J Urol. 2016;195(6):1825-1829. doi:10.1016/j.juro.2015.11.065 | PubMed

📚 La Torre A, Giupponi G, Duffy D, Conca A, Cai T, Scardigli A. Sexual dysfunction related to drugs: a critical review. Part V: α-blocker and 5-ARI drugs. Pharmacopsychiatry. 2016;49(1):3-13. doi:10.1055/s-0035-1565100 PubMed

Lee SS, Yang YW, Tsai TH, et al. 5-alpha-reductase inhibitors and the risk of diabetes mellitus: a nationwide population-based study. Prostate. 2016 Jan;76(1):41-7. doi:10.1002/pros.23097 | PubMed

📚 Liu L, Zhao S, Li F, et al. Effect of 5α-reductase inhibitors on sexual function: a meta-analysis and systematic review of randomized controlled trials. J Sex Med. 2016;13(9):1297-1310. doi:10.1016/j.jsxm.2016.07.006 | PubMed

[Comment] Kaplan SA. Re: Effect of 5α-reductase inhibitors on sexual function: a meta-analysis and systematic review of randomized controlled trials. J Urol. 2018;199(1):8-9. doi:10.1016/j.juro.2017.09.133

🐀 Llidó A, Bartolomé I, Darbra S, Pallarès M. Neonatal finasteride administration decreases dopamine release in nucleus accumbens after alcohol and food presentation in adult male rats. Behav Brain Res. 2016;309:44-50. doi:10.1016/j.bbr.2016.04.047 | PubMed

Maeda T, Kikuchi E, Hasegawa M, et al. A prospective longitudinal survey of erectile function status in symptomatic benign prostatic hyperplasia patients treated with dutasteride. Aging Male. 2016 Jun;19(2):111-6. doi:10.3109/13685538.2016.1156082 | PubMed

Kaplan SA. Re: A prospective longitudinal survey of erectile function status in symptomatic benign prostatic hyperplasia patients treated with dutasteride. J Urol. 2017 Sep;198(3):459. doi:10.1016/j.juro.2017.06.032 | PubMed

Molina-Leyva A, Caparros-Del Moral I, Gomez-Avivar P, Alcalde-Alonso M, Jimenez-Moleon JJ. Psychosocial impairment as a possible cause of sexual dysfunction among young men with mild androgenetic alopecia: a cross-sectional crowdsourcing web-based study. Acta Dermatovenerol Croat. 2016;24(1):42-48. Europe PMC | Journal site

Motofei IG, Rowland DL, Georgescu SR, et al. Finasteride adverse effects in subjects with androgenic alopecia: A possible therapeutic approach according to the lateralization process of the brain. J Dermatolog Treat. 2016;27(6):495-497. doi:10.3109/09546634.2016.1161155 | PubMed

Motofei IG, Rowland DL, Georgescu SR, Tampa M, Baleanu BC, Paunica S. Are hand preference and sexual orientation possible predicting factors for finasteride adverse effects in male androgenic alopecia? Exp Dermatol. 2016;25(7):557-558. doi:10.1111/exd.13003 | PubMed

Mysore V, Shashikumar BM. Guidelines on the use of finasteride in androgenetic alopecia. Indian J Dermatol Venereol Leprol. 2016;82(2):128–134. doi:10.4103/0378-6323.177432 | PubMed

Oelke M, Martinelli E. [Pharmacological treatment of benign prostatic hyperplasia]. Urologe A. 2016;55(1):81-94; quiz 95-96. doi:10.1007/s00120-015-0011-3 | PubMed

Paunica S, Giurgiu M, Vasilache A, Paunica I, Motofei I, Vasilache A, Dumitriu HT, Dumitriuv AS. Finasteride adverse effects and post-finasteride syndrome; implications for dentists. Journal of Mind and Medical Sciences. 2016;3(1):71-79. Accessed May 14, 2021.

Pirozzi Farina F, Pischedda A. Comments concerning the real risk of sexual adverse events secondary to the use of 5-ARIs. Arch Ital Urol Androl. 2016;87(4):312-316. doi:10.4081/aiua.2015.4.312 | PubMed

Seale LR, Eglini AN, McMichael AJ. Side effects related to 5 α-reductase inhibitor treatment of hair loss in women: a review. J Drugs Dermatol. 2016;15(4):414-419. Journal site | PubMed

Soggiu A, Piras C, Greco V, et al. Exploring the neural mechanisms of finasteride: a proteomic analysis in the nucleus accumbens. Psychoneuroendocrinology. 2016;74:387–396. doi:10.1016/j.psyneuen.2016.10.001 | PubMed

Tsunemi Y, Irisawa R, Yoshiie H, et al; ARI114264 Study Group. Long-term safety and efficacy of dutasteride in the treatment of male patients with androgenetic alopecia. J Dermatol. 2016 Sep;43(9):1051-8. doi:10.1111/1346-8138.13310 | PubMed

Unger JM, Till C, Thompson IM, et al. Long-term consequences of finasteride vs placebo in the Prostate Cancer Prevention Trial. J Natl Cancer Inst. 2016;108(12). doi:10.1093/jnci/djw168 | PubMed

Welliver C, Essa A. Sexual side effects of medical and surgical benign prostatic hyperplasia treatments. Urol Clin North Am. 2016;43(3):393–404. doi:10.1016/j.ucl.2016.04.010 | PubMed

Wu M, Yu Q, Li Q. Differences in reproductive toxicology between alopecia drugs: an analysis on adverse events among female and male cases. Oncotarget. 2016;7(50):82074-82084. doi:10.18632/oncotarget.12617 | PubMed

Zhang C, Li K, Yang Z, Wang Y, Si H. The effect of the aqueous extract of Bidens pilosa L. on androgen deficiency dry eye in rats. Cell Physiol Biochem. 2016;39(1):266-77. doi:10.1159/000445622 | PubMed

2016 abstracts

Butcher M, Baas W, Lwin A, et al. MP89-08 Post-finasteride syndrome: real or imagined? Journal of Urology. 2016;195(4S):e1139. doi:10.1016/j.juro.2016.02.2469

Fiuk J, Butcher M, Kohler T, McVary K. 133 Female post-finasteride syndrome: It’s not just a man’s world. Journal Sex Med. 2016 May 1;13(5, Suppl 1):S62-S63. doi:10.1016/j.jsxm.2016.02.139

Georgescu SR, Paunica S, Tampa M, et al. 200 Uncommon finasteride side effects in male androgenic alopecia. J Invest Dermatol. ESDR 2016 Annual Meeting Abstract Supplement: Hair and Other Adnexal Structures. 2016 Sep 1;136(9, Suppl 2):S195. doi:10.1016/j.jid.2016.06.219.

Lwin A, Butcher M, Holland B, et al. 054 Post finasteride syndrome: Guess who—demographics from FDA database. J Sex Med. 2016;13(5, Supplement 1):S26. doi:10.1016/j.jsxm.2016.02.057

Bibliographies: 2016–present | 2011–2015 | 2000–2010 | 1942–1999